370 related articles for article (PubMed ID: 30112436)
21. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
Niegisch G
Methods Mol Biol; 2023; 2684():293-301. PubMed ID: 37410242
[TBL] [Abstract][Full Text] [Related]
22. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
Abel M; Burkenroad A; Sun A; Lu E; Stefanoudakis D; Drakaki A
Clin Genitourin Cancer; 2021 Jun; 19(3):183-193. PubMed ID: 33558159
[TBL] [Abstract][Full Text] [Related]
23. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
[TBL] [Abstract][Full Text] [Related]
24. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.
Faltas B; Goldenberg DM; Ocean AJ; Govindan SV; Wilhelm F; Sharkey RM; Hajdenberg J; Hodes G; Nanus DM; Tagawa ST
Clin Genitourin Cancer; 2016 Feb; 14(1):e75-9. PubMed ID: 26541586
[TBL] [Abstract][Full Text] [Related]
25. Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
Tassinari E; Mollica V; Nuvola G; Marchetti A; Rosellini M; Massari F
Cancer Manag Res; 2022; 14():1945-1960. PubMed ID: 35720644
[TBL] [Abstract][Full Text] [Related]
26. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
Zhang X; Huang AC; Chen F; Chen H; Li L; Kong N; Luo W; Fang J
Antib Ther; 2022 Jan; 5(1):18-29. PubMed ID: 35146330
[TBL] [Abstract][Full Text] [Related]
27. Antibody-drug conjugates for the treatment of urothelial carcinoma.
Ravi P; McGregor BA
Expert Opin Biol Ther; 2021 Jul; 21(7):915-922. PubMed ID: 32589063
[TBL] [Abstract][Full Text] [Related]
28. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
29. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
30. Novel antibody-drug conjugates for triple negative breast cancer.
Nagayama A; Vidula N; Ellisen L; Bardia A
Ther Adv Med Oncol; 2020; 12():1758835920915980. PubMed ID: 32426047
[TBL] [Abstract][Full Text] [Related]
31. Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan.
Fontes MS; Vargas Pivato de Almeida D; Cavalin C; Tagawa ST
Onco Targets Ther; 2022; 15():1531-1542. PubMed ID: 36575731
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
Abbas M; Heitplatz B; Bernemann C; Boegemann M; Trautmann M; Schrader AJ; Wardelmann E; Schlack K
Oncol Lett; 2023 Dec; 26(6):527. PubMed ID: 38020299
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor in bladder cancer: A promising therapeutic target.
Tripathi A; Gupta S
Asian J Urol; 2020 Jul; 7(3):284-290. PubMed ID: 32742928
[TBL] [Abstract][Full Text] [Related]
34. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
35. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
[TBL] [Abstract][Full Text] [Related]
37. Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates.
Nieto-Jiménez C; Sanvicente A; Díaz-Tejeiro C; Moreno V; Lopez de Sá A; Calvo E; Martínez-López J; Pérez-Segura P; Ocaña A
Clin Transl Med; 2023 Sep; 13(9):e1329. PubMed ID: 37740463
[TBL] [Abstract][Full Text] [Related]
38. Antibody-Drug Conjugates in Uro-Oncology.
Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
[TBL] [Abstract][Full Text] [Related]
39. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
40. Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma.
Fenton SE; VanderWeele DJ
Front Oncol; 2022; 12():1069356. PubMed ID: 36686762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
